Milk Thistle: The Definitive Guide

What is milk thistle?

Milk thistle is Silybum marianum, a flowering plant in the daisy family. Its seed extract is marketed for “liver support.” The main extract constituent, silymarin, is itself a mixture of flavonolignans; silybin, also called silibinin, is one component.

That naming matters. A whole-seed powder, a standardized silymarin capsule, a silybin-phospholipid complex and intravenous silibinin can produce different exposures. Intravenous silibinin used in specialist poisoning care does not validate an oral supplement for routine liver disease.

Typical Milk Thistle Protocols

No RDA, AI or UL exists for milk thistle or silymarin. These research regimens are not interchangeable with a store product whose extract and standardization differ.

Botanical and plant part

Record Silybum marianum and whether the product uses seed extract or another material.

Extract identity

Keep total extract mass, declared silymarin and named silybin amounts separate.

Administration

Record amount per administration and frequency; 700 mg three times daily is not 700 mg total per day.

Clinical context

Preserve diagnosis, medications, alcohol exposure, baseline labs and the clinician-directed endpoint.

What is milk thistle commonly used for?

Products are promoted for fatty liver, hepatitis, alcohol-related liver injury, medication or toxin exposure, glucose control and general “detox.” NCCIH concludes that high-quality evidence is insufficient for definite conclusions and that liver-disease trials are conflicting or too limited. [1]

“Detox” is not a defined clinical endpoint. The liver already performs metabolism and excretion; an abnormal ALT, jaundice, dark urine, severe abdominal pain, confusion or suspected poisoning needs clinical assessment.

Which forms and labels matter?

Look for the Latin name, seed or plant part, extraction ratio, total extract per unit, silymarin standardization, named flavonolignans, serving size, lot and independent quality testing. Do not infer one formulation’s exposure from another product’s front-label milligrams.

NCCIH notes that commercial products have shown poor chemical or microbiological quality, including silymarin amounts that differ from the label and contamination by pesticides, microorganisms or mycotoxins. [1]

What does the human evidence show?

Fried randomized 154 people with chronic hepatitis C and elevated ALT after unsuccessful interferon therapy. Participants received placebo or silymarin 420 or 700 mg three times daily for 24 weeks. Two people in each group met the primary ALT outcome; changes in ALT, HCV RNA and quality of life did not significantly differ. Tolerability was comparable with placebo. [2]

Navarro randomized 78 adults with presumed non-cirrhotic NASH to Legalon 420 mg, 700 mg or placebo three times daily for 48–50 weeks. The intention-to-treat primary outcome, a two-point NAS reduction, occurred in 19%, 15% and 12%, respectively, without a significant group difference. Central review found only 29 participants actually met the intended histologic criteria, limiting precision. The linked correction changes the fourth author’s surname from Adfhal to Afdhal, not the findings. [3][5]

Wah Kheong randomized 99 people with biopsy-proven NASH to 700 mg silymarin or placebo three times daily for 48 weeks. The primary outcome, at least a 30% NAS reduction, occurred in 32.7% versus 26.0% and was not significant. Secondary fibrosis findings favored silymarin, but the authors called for confirmation in a larger trial. [4]

These trials address specific diagnosed liver conditions and formulations. Their neutral primary results do not prove that every milk thistle product is inactive for every purpose, but they do undercut confident treatment and “liver repair” claims.

How might it work?

Laboratory and animal work proposes antioxidant, anti-inflammatory, membrane and antifibrotic actions for silymarin flavonolignans. Those mechanisms can justify study questions; they do not establish clinical benefit. Oral absorption, metabolism and product composition also limit transfer from a laboratory concentration to a retail capsule.

What are the risks and interactions?

Oral milk thistle appears generally well tolerated; bloating, nausea and gas are common reported effects. Allergy is possible, especially with ragweed, chrysanthemum, marigold, daisy or other Asteraceae allergy. Pregnancy and breastfeeding safety remains poorly defined. [1]

Review use with all medicines. Laboratory interaction hypotheses involving drug-metabolizing enzymes or transporters do not predict every clinical interaction, but diabetes medicines, narrow-therapeutic-index drugs and cancer treatment warrant particular review. A supplement should not delay investigation of abnormal liver tests or replace antiviral, metabolic or toxicology care.

Status in the United States and Canada

In the United States, oral milk thistle products are sold as dietary supplements and are not FDA-approved treatments for hepatitis, NASH or cirrhosis.

In Canada, authorized natural health products have product-specific licences and label conditions. A product licence does not establish equivalence to Legalon or approval to treat serious liver disease.

What should be monitored?

Record product, lot, plant part, extract and standardized amount, administration time, missed doses, symptoms, medicines, alcohol exposure and clinician-directed laboratory dates. Keep laboratory, fasting status and medication context comparable when reviewing trends.

What happens after stopping?

No withdrawal syndrome or standard taper is established. Do not use stopping or continuing a supplement as a substitute for investigation, prescribed therapy or scheduled liver monitoring.

How should it be stored?

Follow the finished-product label, protect it from heat and moisture, retain the lot and expiry date and keep it out of children’s reach. Discard products with damaged seals, unexpected odor, moisture or a recall notice.

Community experiences

Anecdotes often combine diet changes, alcohol reduction, weight change, prescribed treatment and several supplements. A lower enzyme value after starting milk thistle cannot isolate cause, and a normal enzyme result does not exclude liver disease.

How does it compare with other approaches?

Cause-specific care has a clearer clinical role: antiviral treatment for hepatitis C, metabolic and weight-management care for fatty liver disease, alcohol treatment where relevant, medication review for drug injury and emergency toxicology for poisoning. Milk thistle has not shown equivalent disease-control evidence.

Frequently asked questions

Is silymarin the same as milk thistle?

No. Milk thistle is the plant; silymarin is a seed-extract mixture; silybin or silibinin is one constituent.

Did the large hepatitis C trial work?

No significant benefit appeared on the primary ALT outcome, HCV RNA or quality of life at 420 or 700 mg three times daily for 24 weeks. [2]

Did the NASH trials show benefit?

Both cited NASH trials were neutral on their primary outcomes. One reported secondary fibrosis signals that need confirmation. [3][4]

Does milk thistle “detox” the liver?

“Detox” is not a defined outcome in these trials. It should not replace a diagnosis or cause-specific care.

Is intravenous silibinin the same as an oral capsule?

No. Route, formulation, exposure and care setting differ, so specialist poisoning use cannot be transferred to retail oral supplements.

What did the Navarro correction change?

It corrected author Nezam Afdhal’s surname. It did not change the protocol or results. [5]

Glossary

Terms used in this guide.

Milk thistle

The flowering plant Silybum marianum.

Silymarin

A mixture of flavonolignans extracted mainly from milk thistle seed.

Silybin / silibinin

A major silymarin constituent; formulation and route still matter.

ALT

Alanine aminotransferase, a blood enzyme used in liver assessment.

NASH

Nonalcoholic steatohepatitis, now often termed metabolic dysfunction-associated steatohepatitis.

NAS

NAFLD Activity Score, a research histology score rather than a complete clinical diagnosis.

How this guide was researched

This draft anchors the overall conclusion in the current NCCIH review and three randomized trials with exact protocols. Evidence checked October 9, 2026.

How this guide was made

The research ledger preserves product, per-administration amount, frequency, duration, population, primary result, open-access scope and corrections.

Sources

Related guides